Great article with a wonderfully broad sweep across brain research, thanks, I learned a lot.
That was some session with Andrew Miller, I would love to have been there (OK, I wouln't have lasted 5 minutes, but you know what I mean), really fascinating and such a shame he won't be pursuing his work on CFS - he has a fine record in brain research. Do you know when his paper will be published?
A note of caution, though. Brain studies are rarely, if ever, conclusive. Most brain-probing equipment e.g. MRI are expensive and time-consuming to use, so sample sizes tend to be very small. Without multiple replications the findings are indicative rather than definitive. That's certainly the case for the studies (well, abstracts) I've just looked at linking fatigue with dopamine or the basal ganglia. These are still early days.
I like the way Ben Natelson and Dikoma Shungu are evaluating several different brain abnormalities at once: assessing cognitive performance, blood flows and biochemical composition (eg lactate) [Research 1st article you link to]. If they can replicate multiple abnormalities in the same patients that will start to look really convincing.
A recent Miller paper suggested that the same processes occurring in IFN-a induced fatigue in hepatitis may be occurring in ME/CFS. Tying the fatigue processes in hepatitis C treatment and ME/CFS together would be a huge boost for ME/CFS
That's very interesting - do you have a reference? The MRC recently agreed funding for a
UK study on fatigue and IFN-alpha (which I
blogged about here).
Re
molecular signatures during IFN-a therapy:
Genome-wide transcriptional profiling was performed on peripheral blood mononuclear cells (PBMCs) from 21 patients with chronic hepatitis C virus (HCV) either awaiting IFN-? therapy (n=10) or at 12 weeks of IFN-? treatment (n=11).
That's an awfully small sample for gene expression profiling, especially using a genome-wide chip, where false positives are very likely because of the huge number of genes analysed. The Lights, who have significantly larger samples in their work, use Quantitative Real-Time PCR (QT-PCR) to measure transciption, which is a more accurate process than microarrays. Best practice is, apparently, to use microarray chips (on larger samples) to identify interesting genes then follow-up with QT-PCR on those interesting genes. So this study is an intriguing pointer, but I'm not sure its any more than that at this stage.
And I agree the
Insular Cortex is a really interesting candidate for playing a key role in ME. Incidentally, there is some evidence that the
Insular Cortex works intimately with the Anterior Cingulate Cortex (ACC), which your piece also mentions as having a possible role in ME.
(Can't help thinking just how much ME is advancing the whole of medical understanding).
I certainly agree that when we finally do crack ME it will involve a breakthrough in understanding how the body/brain works. Whatever the 'thing' is that is broken in ME/CFS is, I strongly suspect it is something that is largely unknown to medicine today.
It's discouraging and surprising that there isn't a whole lot to show in those diseases that have been recognized to have damage to the brain; and they receive so much more funding.
Maybe we shouldn't be so surprised, or discouraged: the brain is regularly described as 'the last great frontier in biology' and is easily the most complex thing in the known universe - so getting anywhere is not going to be easy.